Yahoo2h
AbbVie’s Elahere wins European approval for certain ovarian cancers
GlobalData market analysts predict that Elahere could generate up to $1.98bn in revenue for AbbVie by 2030. Credit: ...
Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip
Alas, this master plan is now in serious doubt. On Nov. 11, the pharmaceutical giant reported that emraclidine failed to meet ...
pharmaphorum2h
AbbVie bags EU nod for key drug from ImmunoGen takeover
AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...
AbbVie Gets European OK of Elahere in Platinum-Resistant Ovarian Cancer
Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion ...
pharmaphorum5h
Syndax gets FDA okay for first-in-class leukaemia drug
Revuforj is Syndax's second first-in-class approval for 2024, coming after the company and partner Incyte got a green light ...
BioSpace9h
AbbVie’s Setback Gives BMS Commanding Lead in Schizophrenia Space
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
AbbVie's (NYSE:ABBV) Shareholders Will Receive A Bigger Dividend Than Last Year
AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 14th of February ...